The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Naveen Pemmaraju, MD, discusses what the early data with eprenetapopt in combination with azacitidine could mean for the future in MDS and AML.

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Courtney DiNardo, MD, MSCE, discusses the results of the analysis evaluating the timing of response to venetoclax-based combinations, and related disease features, in older patients with AML.

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Brandon G. Smaglo, MD, FACP, discusses the role of immunotherapy in advanced gastric cancer.

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.